SANOFI : Sarclisa® (isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma
MarketScreener,
Media Update Sarclisa® (isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease…